Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.

Journal Article (Journal Article)

BACKGROUND: Patent ductus arteriosus (PDA) is common in extremely premature infants and associated with increased morbidity and mortality. Medical management of PDA uses either indomethacin or ibuprofen. Despite numerous studies, uncertainty exists as to which drug is safer or more effective; we sought to fill this knowledge gap. METHODS: We identified infants <28weeks gestational age discharged from neonatal intensive care units included in the Pediatrix Medical Group Clinical Data Warehouse between 2006 and 2012 who were treated with indomethacin or ibuprofen between postnatal days 2 and 14. Infants treated with both drugs or infants with a congenital malformation were excluded. We used multivariable logistic regression to determine the association of indomethacin versus ibuprofen on clinical outcomes. RESULTS: Of 6349 patients who met study criteria, 1177 (19%) received ibuprofen and 5172 (81%) received indomethacin. The median gestational age was 25weeks (interquartile range 24-26), and 2894 (46%) infants were <750g at birth. On unadjusted analysis, infants who received ibuprofen had significantly higher incidences of death prior to discharge, surgical ligation of the PDA prior to discharge, death or spontaneous intestinal perforation within 7days of therapy, death or surgical ligation of the PDA prior to discharge, and an elevated creatinine within 7days of treatment. However, on multivariable analysis, no significant differences in outcomes were observed (odds ratio for death/PDA ligation for ibuprofen vs. indomethacin=1.12 [95% CI 0.91-1.39]). CONCLUSIONS: We observed similar effectiveness and safety profiles for indomethacin and ibuprofen in the medical management of PDA in premature infants.

Full Text

Duke Authors

Cited Authors

  • Gulack, BC; Laughon, MM; Clark, RH; Sankar, MN; Hornik, CP; Smith, PB

Published Date

  • December 2015

Published In

Volume / Issue

  • 91 / 12

Start / End Page

  • 725 - 729

PubMed ID

  • 26386610

Pubmed Central ID

  • PMC4662898

Electronic International Standard Serial Number (EISSN)

  • 1872-6232

Digital Object Identifier (DOI)

  • 10.1016/j.earlhumdev.2015.08.003


  • eng

Conference Location

  • Ireland